Advanced search
Start date

Novel strategies for eliminating residual tumor cells using epigenetic therapy

Grant number: 19/23480-4
Support type:Regular Research Grants
Duration: March 01, 2020 - February 28, 2022
Field of knowledge:Biological Sciences - Biochemistry - Molecular Biology
Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
Principal Investigator:Miriam Galvonas Jasiulionis
Grantee:Miriam Galvonas Jasiulionis
Principal investigator abroad: Gangning Liang
Institution abroad: University of Southern California (USC), United States
Home Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
Associated research grant:18/20775-0 - Non-coding RNAs involved with melanoma genesis and progression, AP.R


This proposal aims to strength our hypothesis that epi-drugs, such as demethylating agents, can be an effective treatment for eliminating residual tumor cells by treating both resistant and/or dormant tumor cells (seed) and the microenvironment (soil). The proposal is based on two immunocompetent models: the cellular model of murine melanoma and the model of microenvironment-dependent tumor growth. These two approaches have a parallel with important aspects in the clinics: the first is related to circulating tumor cells remaining after removing a tumor by surgery (residual tumor cells); alternatively, our model of tumor growth from a very small number of tumor cells induced by the presence of a massive number of apoptotic cells has a parallel with tumor cells remaining after treatments inducing massive apoptosis, such as radio- and chemotherapy, which can favor the growth of remaining viable cells. (AU)